<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04986813</url>
  </required_header>
  <id_info>
    <org_study_id>PHMA/GSMCH-17/IEC-29A</org_study_id>
    <nct_id>NCT04986813</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Trauma Surgery Tranexamic Acid in Trauma Surgery Tranexamic Acid in Trauma Surgery</brief_title>
  <official_title>Efficacy of Tranexamic Acid in Reducing Requirement of Blood Transfusion in Lower Limb Trauma Surgery: A Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaspreet Singh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AP Jain Civil Hospital, Rajpura</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was done to evaluate the efficacy of Tranexamic Acid (TXA) in reducing blood&#xD;
      transfusion requirement in patients of lower limb trauma undergoing surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a single centre, parallel group, prospective randomized control study. 116 patients&#xD;
      of lower limb trauma presented between April 2017 to August 2018 at Civil Hospital Rajpura.&#xD;
      16 patients were excluded due to old fracture, percutaneous wire fixation or non-consenting&#xD;
      patient. The remaining 100 patients were randomized into two groups. 50 patients were given 1&#xD;
      gram of TXA before surgery and 50 patients were not given TXA. Fall in Hb, requirement of&#xD;
      blood transfusion, number of days admitted in the hospital after surgery and evidence of deep&#xD;
      vein thrombosis were monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This was a single centre, parallel group, prospective randomized control study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The random allocation of the patients to either group was done by one of the investigators using a random number table.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Requirement of number of units of blood transfusion</measure>
    <time_frame>Average of 15 days</time_frame>
    <description>From the date of surgery till time of discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evidence of deep vein thrombosis by Wells Score</measure>
    <time_frame>Average of 15 days (From the date of surgery till time of discharge)</time_frame>
    <description>Based on Wells et al Clinical model for DVT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Haemoglobin level post surgery</measure>
    <time_frame>Average of 15 days (From the date of surgery till time of discharge)</time_frame>
    <description>From the date of surgery till time of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days admitted in the hospital after surgery</measure>
    <time_frame>Average of 15 days (From the date of admission till time of discharge)</time_frame>
    <description>From the date of admission till time of discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Tranexamic Acid</condition>
  <condition>Trauma</condition>
  <condition>Lower Extremity Fracture</condition>
  <arm_group>
    <arm_group_label>Group Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients were given 1 gram of Tranexamic acid (TXA) intravenously pre-operatively. Intravenous TXA was administered, at the time of start of surgical incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 patients were kept as a control group and were not given TXA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid injection</intervention_name>
    <description>1 g of TXA in 100 ml of normal saline</description>
    <arm_group_label>Group Tranexamic Acid</arm_group_label>
    <other_name>Inj Tranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>100 ml</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients suffering from lower limb trauma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of old implant or infection at the fracture site,&#xD;
&#xD;
          -  Any blood coagulation disorder&#xD;
&#xD;
          -  Patients undergoing percutaneous wire placement procedures for fracture fixation&#xD;
&#xD;
          -  Polytrauma&#xD;
&#xD;
          -  Non-consenting patients&#xD;
&#xD;
          -  Psychiatric patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gurleen Kaur, MD</last_name>
    <role>Study Director</role>
    <affiliation>Adesh Medical College &amp; Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>APJain Civil Hospital, Rajpura</name>
      <address>
        <city>Patiala</city>
        <state>Punjab</state>
        <zip>140401</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Kaye JA, Jick H. Epidemiology of lower limb fractures in general practice in the United Kingdom. Inj Prev. 2004 Dec;10(6):368-74.</citation>
    <PMID>15583259</PMID>
  </reference>
  <results_reference>
    <citation>Zhang P, Bai J, He J, Liang Y, Chen P, Wang J. A systematic review of tranexamic acid usage in patients undergoing femoral fracture surgery. Clin Interv Aging. 2018 Sep 4;13:1579-1591. doi: 10.2147/CIA.S163950. eCollection 2018. Review.</citation>
    <PMID>30233155</PMID>
  </results_reference>
  <results_reference>
    <citation>Fischer PE, Bulger EM, Perina DG, Delbridge TR, Gestring ML, Fallat ME, Shatz DV, Doucet J, Levy M, Stuke L, Zietlow SP, Goodloe JM, VanderKolk WE, Fox AD, Sanddal ND. Guidance Document for the Prehospital Use of Tranexamic Acid in Injured Patients. Prehosp Emerg Care. 2016 Sep-Oct;20(5):557-9. doi: 10.3109/10903127.2016.1142628. Epub 2016 Mar 17.</citation>
    <PMID>26985786</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>AP Jain Civil Hospital, Rajpura</investigator_affiliation>
    <investigator_full_name>Jaspreet Singh</investigator_full_name>
    <investigator_title>Specialist Medical Officer</investigator_title>
  </responsible_party>
  <keyword>Tranexamic acid</keyword>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Blood transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 5, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT04986813/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

